Provided are pharmaceutical formulations that include an amyloid polypeptide including at least one D-amino acid, and a pharmaceutically acceptable carrier. Also provided are kits that include the pharmaceutical formulations. Methods that employ the pharmaceutical compositions are also provided, as are methods for reducing solubility of an all-L amyloid polypeptide in a fluid, methods for characterizing an amyloid polypeptide of interest, and methods for removing an amyloid polypeptide from a bodily fluid.
